aPL profiles over time (N = 482).
| Baseline | 0–12 M | 12–24 M | 24–36 M | 36–48 M | 48–60 M | |
|---|---|---|---|---|---|---|
| No. patients with follow-up | N/A | 452 | 398 | 357 | 282 | 138 |
| No. patients with aPL results | 482 | 348 | 302 | 245 | 184 | 87 |
| Meaningful aPL profilea | 472 (98) | 254 (73) | 216 (72) | 177 (72) | 135 (73) | 61 (70) |
| Not meaningful aPL profileb | 3 (1) | 31 (9) | 29 (10) | 24 (10) | 14 (8) | 7 (8) |
| Inconclusive aPL profilec | 7 (1) | 63 (18) | 57 (19) | 44 (18) | 35 (19) | 19 (22) |
Values are n (%) unless otherwise indicated.
↵aPositive LAC test and/or aCL/anti-β2-GPI IgG/M ≥ 40 U.
↵bNegative LAC test and aCL/anti-β2-GPI IgG/M < 40 U.
↵cMissing determinant aPL test result(s) (those used to determine the baseline clinically meaningful aPL profile) with no other positive aPL tests, or negative determinant aPL test result(s) with missing other aPL test result(s). aCL: anticardiolipin antibody; anti-β2-GPI: anti-β glycoprotein I antibody; aPL: antiphospholipid antibody; LAC; lupus anticoagulant; M: months.